CNST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CNST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.
Constellation Pharmaceuticals's current deferred revenue for the quarter that ended in Mar. 2021 was $0.00 Mil.The historical data trend for Constellation Pharmaceuticals's Current Deferred Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Constellation Pharmaceuticals Annual Data | |||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||
Current Deferred Revenue | - | - | - | - | - |
Constellation Pharmaceuticals Quarterly Data | ||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
Current Deferred Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Thank you for viewing the detailed overview of Constellation Pharmaceuticals's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Emma Reeve | officer: Chief Financial Officer | C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451 |
Column Group L P | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Karen Valentine | officer: See Remarks | C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421 |
Mark A Goldsmith | director, 10 percent owner | 925 PAGE MILL ROAD, PALO ALTO CA 94304 |
Jeffrey Humphrey | officer: Chief Medical Officer | C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
Steven L. Hoerter | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Elizabeth Trehu | director | C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138 |
Scott Braunstein | director | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
James E Audia | director | 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142 |
Adrian Senderowicz | officer: Chief Medical Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Jigar Raythatha | director, officer: See Remarks | C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Patrick Trojer | officer: Chief Scientific Officer | 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142 |
Richard S Levy | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Ponoi Management, Llc | 10 percent owner, other: General Partner | 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
David V Goeddel | 10 percent owner, other: Managing Partner | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 12-06-2020
By Marketwired Marketwired • 06-17-2021
By Marketwired Marketwired • 09-09-2020
By Marketwired Marketwired • 10-19-2020
By Marketwired Marketwired • 02-18-2021
By Marketwired Marketwired • 01-06-2021
By Marketwired Marketwired • 06-02-2021
By PRNewswire PRNewswire • 06-02-2021
By Business Wire Business Wire • 06-02-2021
By Marketwired Marketwired • 12-06-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.